182 related articles for article (PubMed ID: 35017656)
1. Immuno-genomic characterisation of high-grade serous ovarian cancer reveals immune evasion mechanisms and identifies an immunological subtype with a favourable prognosis and improved therapeutic efficacy.
Sun J; Yan C; Xu D; Zhang Z; Li K; Li X; Zhou M; Hao D
Br J Cancer; 2022 Jun; 126(11):1570-1580. PubMed ID: 35017656
[TBL] [Abstract][Full Text] [Related]
2. A Comprehensive Analysis of Prognostic Indicators in Serous Ovarian Cancer Based on Leukocyte Migration and Immune Microenvironment.
Pan J; Chen X; Yang L; Song Y; Liu J; Li L; Lin Y; Tang L; Qiu S; Xu Q
Front Biosci (Landmark Ed); 2023 Jun; 28(6):130. PubMed ID: 37395023
[TBL] [Abstract][Full Text] [Related]
3. Tumour microenvironment-based molecular profiling reveals ideal candidates for high-grade serous ovarian cancer immunotherapy.
Lu X; Ji C; Jiang L; Zhu Y; Zhou Y; Meng J; Gao J; Lu T; Ye J; Yan F
Cell Prolif; 2021 Mar; 54(3):e12979. PubMed ID: 33522069
[TBL] [Abstract][Full Text] [Related]
4. Integrative proteogenomic analyses of human tumours identifies ADNP as a novel oncogenic mediator of cell cycle progression in high-grade serous ovarian cancer with poor prognosis.
Karagoz K; Mehta GA; Khella CA; Khanna P; Gatza ML
EBioMedicine; 2019 Dec; 50():191-202. PubMed ID: 31767542
[TBL] [Abstract][Full Text] [Related]
5. Classification of High-Grade Serous Ovarian Carcinoma by Epithelial-to-Mesenchymal Transition Signature and Homologous Recombination Repair Genes.
Sohn MH; Kim SI; Shin JY; Kim HS; Chung HH; Kim JW; Lee M; Seo JS
Genes (Basel); 2021 Jul; 12(7):. PubMed ID: 34356119
[TBL] [Abstract][Full Text] [Related]
6. Ovarian cancer mutational processes drive site-specific immune evasion.
Vázquez-García I; Uhlitz F; Ceglia N; Lim JLP; Wu M; Mohibullah N; Niyazov J; Ruiz AEB; Boehm KM; Bojilova V; Fong CJ; Funnell T; Grewal D; Havasov E; Leung S; Pasha A; Patel DM; Pourmaleki M; Rusk N; Shi H; Vanguri R; Williams MJ; Zhang AW; Broach V; Chi DS; Da Cruz Paula A; Gardner GJ; Kim SH; Lennon M; Long Roche K; Sonoda Y; Zivanovic O; Kundra R; Viale A; Derakhshan FN; Geneslaw L; Issa Bhaloo S; Maroldi A; Nunez R; Pareja F; Stylianou A; Vahdatinia M; Bykov Y; Grisham RN; Liu YL; Lakhman Y; Nikolovski I; Kelly D; Gao J; Schietinger A; Hollmann TJ; Bakhoum SF; Soslow RA; Ellenson LH; Abu-Rustum NR; Aghajanian C; Friedman CF; McPherson A; Weigelt B; Zamarin D; Shah SP
Nature; 2022 Dec; 612(7941):778-786. PubMed ID: 36517593
[TBL] [Abstract][Full Text] [Related]
7. High-grade serous tubo-ovarian cancer refined with single-cell RNA sequencing: specific cell subtypes influence survival and determine molecular subtype classification.
Olbrecht S; Busschaert P; Qian J; Vanderstichele A; Loverix L; Van Gorp T; Van Nieuwenhuysen E; Han S; Van den Broeck A; Coosemans A; Van Rompuy AS; Lambrechts D; Vergote I
Genome Med; 2021 Jul; 13(1):111. PubMed ID: 34238352
[TBL] [Abstract][Full Text] [Related]
8. Single-Cell RNA Sequencing Reveals the Tissue Architecture in Human High-Grade Serous Ovarian Cancer.
Xu J; Fang Y; Chen K; Li S; Tang S; Ren Y; Cen Y; Fei W; Zhang B; Shen Y; Lu W
Clin Cancer Res; 2022 Aug; 28(16):3590-3602. PubMed ID: 35675036
[TBL] [Abstract][Full Text] [Related]
9. High expression of fibroblast activation protein (FAP) predicts poor outcome in high-grade serous ovarian cancer.
Li M; Cheng X; Rong R; Gao Y; Tang X; Chen Y
BMC Cancer; 2020 Oct; 20(1):1032. PubMed ID: 33109151
[TBL] [Abstract][Full Text] [Related]
10. Construction of an aging-related risk signature in high-grade serous ovarian cancer for predicting survival outcome and immunogenicity.
Liu S; Liu Y; Ma J; Lv R; Wang F
Medicine (Baltimore); 2023 Sep; 102(35):e34851. PubMed ID: 37657028
[TBL] [Abstract][Full Text] [Related]
11. Immune profiling reveals prognostic genes in high-grade serous ovarian cancer.
Wu Y; Xia L; Zhao P; Deng Y; Guo Q; Zhu J; Chen X; Ju X; Wu X
Aging (Albany NY); 2020 Jun; 12(12):11398-11415. PubMed ID: 32544083
[TBL] [Abstract][Full Text] [Related]
12. Stromal infiltrating mast cells identify immunoevasive subtype high-grade serous ovarian cancer with poor prognosis and inferior immunotherapeutic response.
Cao K; Zhang G; Zhang X; Yang M; Wang Y; He M; Lu J; Liu H
Oncoimmunology; 2021; 10(1):1969075. PubMed ID: 34527431
[TBL] [Abstract][Full Text] [Related]
13. Single-Cell RNA-Sequencing Atlas Reveals the Tumor Microenvironment of Metastatic High-Grade Serous Ovarian Carcinoma.
Deng Y; Tan Y; Zhou D; Bai Y; Cao T; Zhong C; Huang W; Ou Y; Guo L; Liu Q; Yin D; Chen L; Luo X; Sun D; Sheng X
Front Immunol; 2022; 13():923194. PubMed ID: 35935940
[TBL] [Abstract][Full Text] [Related]
14. Combined image and genomic analysis of high-grade serous ovarian cancer reveals PTEN loss as a common driver event and prognostic classifier.
Martins FC; Santiago Id; Trinh A; Xian J; Guo A; Sayal K; Jimenez-Linan M; Deen S; Driver K; Mack M; Aslop J; Pharoah PD; Markowetz F; Brenton JD
Genome Biol; 2014 Dec; 15(12):526. PubMed ID: 25608477
[TBL] [Abstract][Full Text] [Related]
15. Integrative analysis reveals early epigenetic alterations in high-grade serous ovarian carcinomas.
Machino H; Dozen A; Konaka M; Komatsu M; Nakamura K; Ikawa N; Shozu K; Asada K; Kaneko S; Yoshida H; Kato T; Nakayama K; Saloura V; Kyo S; Hamamoto R
Exp Mol Med; 2023 Oct; 55(10):2205-2219. PubMed ID: 37779141
[TBL] [Abstract][Full Text] [Related]
16. Genomic profiling of the residual disease of advanced high-grade serous ovarian cancer after neoadjuvant chemotherapy.
Lee YJ; Kim D; Shim JE; Bae SJ; Jung YJ; Kim S; Lee H; Kim SH; Jo SB; Lee JY; Kim HS; Paik S
Int J Cancer; 2020 Apr; 146(7):1851-1861. PubMed ID: 31603993
[TBL] [Abstract][Full Text] [Related]
17. CCNE1 and BRD4 co-amplification in high-grade serous ovarian cancer is associated with poor clinical outcomes.
Petersen S; Wilson AJ; Hirst J; Roby KF; Fadare O; Crispens MA; Beeghly-Fadiel A; Khabele D
Gynecol Oncol; 2020 May; 157(2):405-410. PubMed ID: 32044108
[TBL] [Abstract][Full Text] [Related]
18. Machine learning-based integration develops an immune-related risk model for predicting prognosis of high-grade serous ovarian cancer and providing therapeutic strategies.
Wu Q; Tian R; He X; Liu J; Ou C; Li Y; Fu X
Front Immunol; 2023; 14():1164408. PubMed ID: 37090728
[TBL] [Abstract][Full Text] [Related]
19. Unraveling tumor-immune heterogeneity in advanced ovarian cancer uncovers immunogenic effect of chemotherapy.
Jiménez-Sánchez A; Cybulska P; Mager KL; Koplev S; Cast O; Couturier DL; Memon D; Selenica P; Nikolovski I; Mazaheri Y; Bykov Y; Geyer FC; Macintyre G; Gavarró LM; Drews RM; Gill MB; Papanastasiou AD; Sosa RE; Soslow RA; Walther T; Shen R; Chi DS; Park KJ; Hollmann T; Reis-Filho JS; Markowetz F; Beltrao P; Vargas HA; Zamarin D; Brenton JD; Snyder A; Weigelt B; Sala E; Miller ML
Nat Genet; 2020 Jun; 52(6):582-593. PubMed ID: 32483290
[TBL] [Abstract][Full Text] [Related]
20. Intratumor heterogeneity and homologous recombination deficiency of high-grade serous ovarian cancer are associated with prognosis and molecular subtype and change in treatment course.
Takaya H; Nakai H; Sakai K; Nishio K; Murakami K; Mandai M; Matsumura N
Gynecol Oncol; 2020 Feb; 156(2):415-422. PubMed ID: 31785864
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
